Jiejie Xu

Shanghai Medical College of Fudan University

Also affiliated with Fudan University, Intelligent Health (United Kingdom)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study”.

Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study

BMC Cancer(2025)10.1186/s12885-025-14870-x

N/A

0DataRank · unranked

0 citations

Kaifeng Jin, Ziyue Xu, Han Zeng, Xiaohe Su, Jingtong Xu +8 more

Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models

Journal of Clinical Investigation(2023)10.1172/jci163291

N/A

0DataRank · unranked

40 citations

Shanshan Deng, Jiejie Xu, Benjamin L. Green, Honghua Zhang, Guofei Cui +13 more